GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rang in Aktien
#3679
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aktienkurs
$27.10
Marktkapitalisierung
$4.59B
Veränderung (1 Tag)
-1.59%
Veränderung (1 Jahr)
-13.54%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategorie
Healthcare
P/B-Verhältnis für GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
P/B-Verhältnis zum October 2026 TTM: 18.70
Laut den neuesten Finanzberichten und dem Aktienkurs von GlaxoSmithKline Pharmaceuticals Limited beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 18.70. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 18.93.
P/B-Verlauf für GlaxoSmithKline Pharmaceuticals Limited von 2004 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 18.70 | -23.00% |
| 2025 | 24.29 | 28.30% |
| 2024 | 18.93 | 46.87% |
| 2023 | 12.89 | 21.54% |
| 2022 | 10.60 | -35.77% |
| 2021 | 16.51 | 41.12% |
| 2020 | 11.70 | 13.72% |
| 2019 | 10.29 | 18.79% |
| 2018 | 8.66 | -25.23% |
| 2017 | 11.58 | -39.20% |
| 2016 | 19.05 | 60.47% |
| 2015 | 11.87 | -7.01% |
| 2013 | 12.77 | 39.51% |
| 2012 | 9.15 | 7.51% |
| 2011 | 8.51 | -16.10% |
| 2010 | 10.15 | 32.71% |
| 2009 | 7.64 | 23.58% |
| 2008 | 6.19 | -1.82% |
| 2007 | 6.30 | -22.76% |
| 2006 | 8.16 | -19.22% |
| 2005 | 10.10 | 38.74% |
| 2004 | 7.28 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 31.9092 | 70.60% |
US
|
|
| 7.3138 | -60.90% |
US
|
|
| -84.6033 | -552.32% |
US
|
|
| 8.6873 | -53.56% |
US
|
|
| 8.4776 | -54.68% |
CH
|
